PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 1

352*5$00$/(21$5'2'$9,1&,

STAGES PRESSO AZIENDE EUROPEE





352*(77281,520$3+$50$75$,1,1*



*8,'$3(5,&$1','$7,



6&$'(1=$





WLURFLQLGLVHLPHVLSHUJOLVWXGHQWLGHOOH)DFROWjGL)DUPDFLD6FLHQ]HH0HGLFLQD ODXUHHLQ

)DUPDFLD&KLPLFDH7HFQRORJLD)DUPDFHXWLFKH&KLPLFD&KLPLFD,QGXVWULDOH6FLHQ]H

%LRORJLFKH0HGLFLQDH&KLUXUJLD HFRUULVSRQGHQWLODXUHHVSHFLDOLVWLFKH H%LRWHFQRORJLH

VRORODXUHHVSHFLDOLVWLFKH 



/ DPPRQWDUHGHLFRQWULEXWLqGLFLUFD¼DOPHVHÊLQROWUHSUHYLVWRXQFRQWULEXWRIRUIHWWDULR

SHUOHVSHVHGLYLDJJLRGRFXPHQWDWHILQRDXQPDVVLPRGL¼



,OEDQGRqGLVSRQLELOHSUHVVR

ZZZXQLURPDLWLQWHUQD]LRQDOHHXURSDSURJOHRQDUGRGHIDXOWKWP

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 2

6200$5,2

 IL BANDO ...... 3 LE DESTINAZIONI ...... 7 REGNO UNITO...... 7 ELI LILLY...... 7 GLAXOSMITHKLINE ...... 8 MERCK SHARP & DOHME...... 9 ASTRAZENECA ...... 10 CELLTECH ...... 11

1(8TEC PHARMA PLC (REGNO UNITO)...... 12 VERNALIS...... 13 GERMANIA ...... 14 AVENTIS...... 14 COLEY PHARMACEUTICAL...... 15 OLANDA...... 16 ORGANON, AKZO NOBEL ...... 16 INTERVET INTERNATIONAL BV...... 17 DANIMARCA ...... 18 LEO-PHARMA...... 18 FRANCIA...... 19 SANOFI-SYNTHELABO ...... 19 PIERRE-FABRE ...... 20 GUERBET ...... 21 CEA ...... 22 BRETAGNE BIOTECHNOLOGIE VEGETALE...... 23 HRA PHARMA ...... 24 ORFAGEN...... 25 IRLANDA...... 26 PREUROCHEM...... 26 SPAGNA ...... 27 ISTITUTO OFTALMOLOGICO DE ALICANTE ...... 27









 PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 3

,/%$1'2





352*5$00$/(21$5'2'$9,1&,



3URJHWWR81,520$3+$50$75$,1,1*



3URPRVVRGD12232/,62QOXV

&RRUGLQDWRGDOO 8QLYHUVLWjGL5RPD/D6DSLHQ]D

LQSDUWHQDULDWRFRQOH8QLYHUVLWjGL5RPD7RU9HUJDWDH5RPD7UH



%$1'2',&21&2562

FRQWULEXWLSHUWLURFLQLGLVHLPHVLSUHVVRD]LHQGHFKLPLFKHHIDUPDFHXWLFKHHXURSHH

Nell’anno accademico 2003/2004 l’Università degli Studi di Roma “La Sapienza” partecipa, mediante il progetto di mobilità UNIROMA-PHARMA-TRAINING, al Programma dell’Unione Europea sulla formazione professionale “Leonardo da Vinci”.

Il tirocinio, attraverso lo svolgimento di attività coerenti con il proprio corso di studio, consentirà ai beneficiari di acquisire una professionalità adeguata alla loro formazione accademica.

Le Università di Roma, “La Sapienza”, “Tor Vergata” e “Roma tre”, partecipanti al Progetto, disporranno di n. 

FRQWULEXWL per tirocini in aziende chimiche e farmaceutiche.

I. IL TIROCINIO:

Il tirocinio formativo è destinato agli VWXGHQWL iscritti, per l’anno accademico 2003/2004 alle seguenti lauree:

8QLYHUVLWj/D6DSLHQ]D

)DFROWjGL)DUPDFLD ¾ Biotecnologie farmaceutiche (2° livello): 1° anno o successivi ¾ Chimica e tecnologia farmaceutiche (ciclo unico): 4° anno o successivi ¾ Farmacia (ciclo unico): 4° anno o successivi

,H,,)DFROWjGL0HGLFLQD ¾ Biotecnologie mediche, molecolari e cellulari (2° livello): 1° anno o successivi ¾ Medicina e Chirurgia (ciclo unico): 4° anno o successivi

)DFROWjGL6FLHQ]H0DWHPDWLFKH)LVLFKHH1DWXUDOL ¾ Biologia applicata alla ricerca biomedica (2° livello): 1° anno o successivi ¾ Biologia cellulare applicata (2° livello): 1° anno o successivi ¾ Biotecnologie genomiche (2° livello): 1° anno o successivi ¾ Biotecnologie industriali e agro-alimentari (2° livello): 1° anno o successivi PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 4

¾ Biotecnologie industriali ed ambientali (2° livello): 1° anno o successivi ¾ Chimica (2° livello): 1° anno o successivi ¾ Chimica (vecchio ordinamento): 4° anno o successivi ¾ Chimica analitica e metodologie applicate (2° livello): 1° anno o successivi ¾ Chimica industriale (vecchio ordinamento): 4° anno o successivi, ¾ Genetica e biologia molecolare (2° livello): 1° anno o successivi ¾ Neurobiologia (2° livello): 1° anno o successivi ¾ Scienze biologiche (vecchio ordinamento): 4° anno o successivi

8QLYHUVLWj7RU9HUJDWD

)DFROWjGL0HGLFLQD ¾ Medicina e Chirurgia (ciclo unico): 4° anno o successivi

)DFROWjGL6FLHQ]H0DWHPDWLFKH)LVLFKHH1DWXUDOL ¾ Biologia cellulare e molecolare (2° livello): 1° anno o successivi ¾ Biologia ed evoluzione umana (2° livello): 1° anno o successivi ¾ Ecologia ed evoluzione (2° livello): 1° anno o successivi ¾ Scienze della nutrizione umana (2° livello): 1° anno o successivi ¾ Chimica (2° livello): 1° anno o successivi

8QLYHUVLWj5RPD7UH

)DFROWjGL6FLHQ]H0DWHPDWLFKH)LVLFKHH1DWXUDOL ¾ Biologia ambientale (2° livello): 1° anno o successivi ¾ Biologia applicata alla ricerca biomedica (2° livello): 1° anno o successivi ¾ Metodologia ed applicazioni della biologia molecolare e cellulare (2° livello): 1° anno o successivi ¾ Scienze biologiche (vecchio ordinamento): 4° anno o successivi

Il tirocinio potrà essere svolto in un'azienda chimica o farmaceutica o in altri Centri di Ricerca che hanno offerto la loro disponibilità ad ospitare gli studenti. La destinazione potrà essere scelta dagli studenti in ordine di graduatoria, previa accettazione della domanda da parte dell'azienda.

6DUjLQGLVSHQVDELOHO¶RWWLPDFRQRVFHQ]DGHOODOLQJXDLQJOHVH.

I tirocini avranno una durata tassativa di PHVL e le partenze si effettueranno all'inizio del mese di IHEEUDLR

, FDQGLGDWLDVVHJQDWDUL GHO FRQWULEXWR /HRQDUGRSRWUDQQR FRQVHJXLUH ODODXUHDVRODPHQWHGRSRDYHUFRQFOXVROR

VWDJHDOO¶HVWHUR

II. LE IMPRESE:

L’attività lavorativa verrà svolta in un’azienda chimica o farmaceutica o in altri Centri di Ricerca di un paese europeo tra cui:

1. (OL/LOO\+ROGLQJV/LPLWHGUnited Kingdom

2. *OD[R6PLWK.OLQH United Kingdom

3. $YHQWLV3KDUPD Germany

4. 0HUFN6KDUS 'RKPHUnited Kingdom

6L ID SUHVHQWH FKH O¶DVVHJQD]LRQH GHO WLURFLQLR q VXERUGLQDWR DOO¶DFFHWWD]LRQH GHOOD GRPDQGD GHOOR VWXGHQWH GD

SDUWHGHOO¶$]LHQGD

III. IL CONTRIBUTO:

L'ammontare dei contributi è di circa 500,00 ¼ DO PHVH GDOOD VXGGHWWD FLIUD YHUUDQQR GHFXUWDWL JOL RQHUL D FDULFR dell'Amministrazione secondo la normativa vigente in Italia. La copertura assicurativa è a carico dell'Ateneo.

È inoltre previsto un contributo forfettario per le spese di viaggio, documentate, fino a un massimo di 300,00 ¼

Le Università organizzeranno appositi corsi di lingua inglese prima delle partenze;

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 5

Il contributo sarà erogato in 2 rate di cui la prima verrà versata prima dell'inizio del tirocinio, se il finanziamento dell’Unione Europea sarà già stato reso disponibile, il conguaglio sarà erogato al rientro dallo stage, previa presentazione dei documenti che giustifichino, in dettaglio, le spese di viaggio e alloggio sostenute nel periodo di stage.

Il Contributo Leonardo sarà soggetto a tassazione secondo la normativa vigente in Italia.

La documentazione relativa alle spese di viaggio e di alloggio dovrà essere presentata HQWUR  JLRUQL dalla data di termine dello stage indicata nel contratto

IV. REQUISITI PER LA PARTECIPAZIONE:

¾ essere iscritti, nell’anno accademico 2003/2004, all'Università di Roma "La Sapienza", "Tor Vergata" o "Roma III" e precisamente: almeno al 1° anno delle lauree specialistiche di 2° livello, oppure almeno al 4° anno di quelle a ciclo unico o del vecchio ordinamento indicate al punto I. ¾ aver superato/ottenuto almeno la metà degli esami/crediti previsti dalle lauree a ciclo unico. Nel caso di studenti iscritti a lauree specialistiche di 2° livello, si farà riferimento alla somma dei crediti della laurea di 1° e 2° livello ¾ Avere una media uguale o superiore a 26/30 (dopo l'eventuale riduzione di 1/30 per ogni anno fuori corso o ripetente) ¾ essere cittadini di uno Stato membro dell'Unione Europea oppure, se cittadini non comunitari, essere residenti in uno Stato membro dell'UE; ¾ non essere residenti o cittadini del Paese in cui si intende svolgere il tirocinio; ¾ non usufruire contemporaneamente di altri contributi alla mobilità su fondi comunitari o d'Ateneo; ¾ non avere usufruito in passato di borse Leonardo da Vinci; ¾ non intrattenere un rapporto di lavoro dipendente al momento della presentazione della domanda.

V. CONOSCENZA LINGUISTICA:

Ê LQGLVSHQVDELOH O¶RWWLPD FRQRVFHQ]D GHOOD OLQJXD LQJOHVH, che dovrà essere dimostrata mediante una delle seguenti attestazioni:

¾ TOEFL ¾ GRE ¾ IELTS ¾ Cambridge First Certificate ¾ Cambridge Certificate of Advanced English ¾ Cambridge Certificate of Proficiency ¾ Cambridge Certificate in English for International Business and Trade (CEIBT) ¾ London Chamber of Commerce English for Business

I candidati in possesso dei requisiti richiesti, che non dispongano di alcun certificato tra quelli indicati, dovranno sostenere unWHVW GLLQJOHVH gratuito, organizzato dalle suddette Università.

VI. PRESENTAZIONE DELLA DOMANDA:

Concorreranno alla selezione solo gli studenti le cui domande saranno pervenute, per via telematica (internet), entro e non oltre le ore GHORWWREUH 

Il modulo di domanda è disponibile alla pagina web: http://www.uniroma1.it/internazionale/europa/prog/leonardo/default.htm potrà essere compilato inserendo il proprio numero di matricola e il codice fiscale.

Al termine dell’operazione verrà rilasciato dal terminale una copia cartacea della domanda.

Tale modulo dovrà essere stampato, debitamente firmato e dovrà prevenire entro LO  RWWREUH alla Rip. IX Rel.

Internazionali dell’Università La Sapienza, oppure essere consegnato alla Rip. IX entro le RUH  GHO  RWWREUH

, unitamente alla seguente documentazione:

¾ 1 fotografia formato tessera ¾ eventuali certificati comprovanti la conoscenza linguistica. ¾ Una fotocopia del bollettino di iscrizione all’anno accademico 2003/2004 PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 6

,QPDQFDQ]DGLTXHVWLGRFXPHQWLODGRPDQGDGLSDUWHFLSD]LRQHSHUYHQXWDRQOLQHQRQYHUUjSUHVDLQHVDPH

VII. SELEZIONE DELLE CANDIDATURE

Le domande saranno valutate da un'apposita Commissione e sarà stilata una lista unica di candidati vincitori e idonei delle tre università di appartenenza.

Secondo l’ordine della lista, i vincitori potranno scegliere una delle destinazioni offerte, tenendo presente che il Centro ospitante potrebbe non accettare la candidatura. In caso di rinuncia dei vincitori avranno diritto al subentro gli idonei sulla base della graduatoria, sino ad esaurimento del numero delle borse. L’Ufficio Relazioni Internazionali avrà cura di informare i candidati idonei, in caso di rinuncia da parte dei vincitori, con una comunicazione scritta.

/D&RPPLVVLRQHVLULVHUYDODSRVVLELOLWjGLYHULILFDUHODPRWLYD]LRQHGHOFDQGLGDWRPHGLDQWHXQFROORTXLR

Si fa presente che i risultati delle selezioni verranno comunicati esclusivamente tramite:

¾ Affissione delle graduatorie presso gli Uffici Relazioni Internazionali delle tre Università ¾ Pubblicazione agli indirizzi web delle Relazioni Internazionali dei tre Atenei.

VIII. CRITERI PER LA VALUTAZIONE DELLE DOMANDE:

Ai fini della formulazione della graduatoria dei vincitori e degli idonei, le domande saranno valutate da una Commissione selezionatrice unica per i tre Atenei. Nel formulare le graduatorie verrà preso in considerazione: ¾ la media corretta dei voti degli esami (ridotta di 1/30 per ogni anno fuori corso o ripetente), considerando il 26 come valore minimo ¾ il numero complessivo degli esami sostenuti o crediti ottenuti, considerando come valore minimo per la partecipazione la meta' degli esami/crediti previsti dalle lauree a ciclo unico o dai due livelli delle lauree a due cicli. ¾ la conoscenza della lingua inglese ¾ le motivazioni e gli obiettivi dello stage

IX. ACCETTAZIONE DEL CONTRIBUTO

Gli assegnatari dovranno sottoscrivere l’accettazione del contributo presentandosi, nei consueti orari di ricevimento, presso la stanza 12 della Rip. IX Relazioni Internazionali – Palazzo del Rettorato entro e non oltre  JLRUQL dalla pubblicazione della graduatoria,

&RORURFKHQRQVLSUHVHQWHUDQQRHQWURLOWHUPLQHLQGLFDWRVDUDQQRFRQVLGHUDWLULQXQFLDWDUL. I candidati idonei che, in caso di rinuncia dei vincitori, verranno contattati dall’Ufficio Relazioni Internazionali, dovranno presentarsi all’Ufficio nei consueti orari di ricevimento entro  JLRUQL per firmare l’accettazione del contributo.

X. UFFICI DI RIFERIMENTO:

Per eventuali informazioni, gli studenti interessati potranno rivolgersi alle Relazioni Internazionali dell’Ateneo di appartenenza, ai seguenti indirizzi di posta elettronica:

¾ Università “La Sapienza”: [email protected] ¾ Università di Tor Vergata: [email protected] ¾ Università di Roma 3: [email protected] Roma, li 09.09.2003

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 7

/('(67,1$=,21,

5(*1281,72

(/,/,//<



:HEVLWH: http://www.lilly.com



(UO:RRG0DQRU:LQGOHVKDP6XUUH\8QLWHG.LQJGRP 5HVHDUFK&HQWHU 



Eli Lilly & Co Ltd. is a global pharmaceutical company, which develops and provides innovative products for prevention and treatment of human disease. The corporate centre is Indianapolis. The profile of compounds in the clinic cover aspects of infectious diseases, cancer, diabetes, osteoporosis, psychiatric and neurological diseases. In the last few years, the best selling compound was the antidepressant Prozac, until it went off patent. Its place has been taken by Xyprexa for the treatment of schizophrenia and bipolar disease. The Lilly Research Centre at Erl Wood, just outside London, operates as a scientifically independent group so that we have the facilities normally expected of a world-ranking neuroscience discovery group. It was here that Xyprexa was discovered. Our efforts are solely directed toward psychiatric and neurological diseases. Specifically related to the Leonardo da Vinci Studentships, we have imaging facilities for both multi-well and single cell applications, transmitter release assays both for endogenous and radiolabelled transmitters, in vitro organ bath assays, electrophysiological techniques from single channel analysis through to in vivo studies including EEG recording, brain microdialysis and behavioural assays. Additionally we have access to even wider technologies at the parent company in Indianapolis. The Company has a training policy for all new employees including students. This includes several Health and Safety, Notebook, Asset Protection, IT, Animal Experimentation (Home Office Licence) modules, etc. - compliance with these is a site requirement. Additionally there are training modules tailored to individual needs in computer hardware and software, including several data analysis packages.

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Farmacia, Chimica e Tecnologia Farmaceutiche, Scienze Biologiche, Medicina e Chirurgia (e corrispondenti lauree specialistiche) e Biotecnologie

(solo lauree specialistiche) PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 8

*/$;260,7+./,1(

:HEVLWH: http://www.gsk.com/index.htm

1HZ)URQWLHUV6FLHQFH3DUN+DUORZ(VVH[8. 5HVHDUFK&HQWHU 

GlaxoSmithKline (GSK) is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK's research is split into 3 disciplines: Genetics Research, Discovery Research and Drug Discovery. Drug discovery is divided into 6 centres of excellence. The Psychiatry centre of excellence for drug discovery (CEDD) is based in Harlow (UK) and Verona (Italy) and supports the progression of drugs to treat depression, anxiety, bipolar depression, schizophrenia, sleep disorders, ADHD and drug dependency.

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Farmacia, Chimica e Tecnologia Farmaceutiche,

Medicina e Chirurgia

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 9

0(5&.6+$53 '2+0(

:HEVLWH http://www.merck.com

1HXURVFLHQFH5HVHDUFK&HQWUH7HUOLQJV3DUN+DUORZ(VVH[





 Merck, Sharpe & Dohme is a leading research-driven pharmaceutical products and services company. Merck discovers, manufactures and markets a broad range of innovative products to improve human health. Situated at Terlings Park on the rural Hertfordshire and Essex borders in the south-east of England, The Neuroscience Research Centre is one of the world's premier scientific institutes researching into disorders and diseases of the brain. Our goal is to develop effective treatments that will improve the quality and extend the lives of patients suffering from neurological and psychiatric diseases. The Neuroscience Research Centre (NRC) is part of Merck Sharp & Dohme, the UK subsidiary of Merck & Co., Inc. We have close links with Merck's other basic research facilities around the world. We work especially closely with our new research centre in San Diego, California which, like Terlings Park, is completely dedicated to central nervous system research.The NRC continually publishes a wide body of research in many different areas. Our most visible achievements so far have been work in the fields of migraine headache and psychiatric disease 0LJUDLQH KHDGDFKH research efforts have resulted in the 5-HT1B/1D receptor selective agonist anti-migraine drug MAXALT© (rizatriptan). (Information on MAXALT© for United States residents is available from our US parent site). 'HSUHVVLRQ the NRC's preclinical work on depression has provided the foundation for clinical trials with antagonists to the neuropeptide substance P, resulting in the discovery that substance P neurokinin-1 receptor antagonists are efficacious in the treatment of depression (published in Science, Vol.281, pp. 1640-1645, 1998).

$Q[LHW\: the NRC's research on receptors for the neurotransmitter GABA has identified an avenue for the development of improved drugs for anxiety (published in Nature Neuroscience, Vol.3, pp. 587-595, 2000).

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, Chimica e Tecnologia Farmaceutiche e corrispondenti lauree specialistiche. PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 10



$675$=(1(&$

:HEVLWH http://www.astrazeneca.com/

$VWUD=HQHFD5 '&KDUQZRRG/RXJKERURXJK8. 5HVHDUFK&HQWHU 



AstraZeneca is one of the world's leading pharmaceutical companies. Our work provides innovative, effective medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, central nervous system, gastrointestinal, infection, pain control and respiratory. R&D Charnwood is one of AstraZeneca's six major research and development sites and is located at Loughborough, in the heart of Leicestershire. Our research capabilities are focused mainly on two disease areas - Respiratory and Inflammation. In Respiratory the targets are asthma; the chronic obstructive pulmonary diseases of bronchitis and emphysema; and the nasal symptoms of seasonal or perennial allergic rhinitis. In Inflammation the key targets are rheumatoid and osteo arthritis. The prevention of transplant rejection and the skin disorder psoriasis are also being approached. The site also has four major Development capabilities which support AstraZeneca's world-wide research outputs. Process R&D prepares the bulk quantities of a new compound which are required for the extensive development programmes. Pharmaceutical and Analytical R&D develop the delivery devices and dosage forms which turn a new compound into a marketable medicine. Clinical provides the expertise needed to design the studies which will administer the potential new medicines to people for the first time. Regulatory ensure the right information is being prepared for Government regulators world-wide. Within a performance driven culture, our employees are encouraged and supported in developing their potential to the full, in line with business needs. This is against a background of equal opportunity where individual success is based on personal merit and performance. As part of our investment in people, we have increased the number of staff by over 500 since 1995. This brings the current total to 1,200, plus 200 temporary staff and contractors. Our highly qualified, multidisciplinary workforce, includes people with specialised skills and experience. Over two thirds are graduates, many with PhDs or MDs. Just seven miles from Loughborough and easily accessible is East Midlands Airport which offers a number of National and European scheduled services. Birmingham International Airport, about 45 minutes by road, provides a wide range of scheduled flights within the UK to many European and North American destinations plus world-wide with transfers.



6WDJHVSHUVWXGHQWLGHL&RUVLGL/DXUHDLQMedicina e Chirurgia (&OLQLFDO3KDUPDFRORJ\8QLW); Chimica, Chimica Industriale, Farmacia, Chimica e Tecnologia Farmaceutiche e corrispondenti lauree specialistiche (3KDUPDFHXWLFDODQG$QDO\WLFDO5HVHDUFK 'HYHORSPHQW8QLW). PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 11

&(//7(&+

:HEVLWH http://www.celltechgroup.com/

*UDQWD3DUN&DPEULGJH8. 5HVHDUFK&HQWHU 



Celltech Group is a fully integrated biopharmaceutical company, with exceptional drug discovery capabilities focused in its core therapeutic areas of autoimmune and inflammatory disorders, cancer, and bone biology. Celltech R&D, the discovery and development business within Celltech Group, employs over 450 research scientists engaged in the discovery of novel human therapies. Based at three research sites in Seattle (US), Slough (UK), and Cambridge (UK), Celltech R&D is pursuing both antibody- and small- molecule-based therapeutics, with a broad range of expertise, capabilities, and methods. Celltech has a leading position in antibody technologies, in particular the design, expression, and production of antibody therapeutics. These efforts have primarily been based at the Slough research centre, though these skills have been extended to the Seattle research centre, where they have been combined with existing gene discovery skills to assist in the rapid validation of novel targets. Celltech's strategy is to develop a strong biology platform investigating disease-related mechanisms of inflammatory cell damage and understanding target tissue and infiltrating cell interactions. In particular, substantial expertise is being assembled in T-cell biology with the aim of identifying and validating new drug targets for immunomodulatory agents. Celltech's small molecule pipeline and discovery research reflect Celltech's primary focus in the areas of autoimmune and inflammatory diseases and cancer. Celltech has substantial medicinal chemistry capabilities, carried out at both its Cambridge and Slough research centres, which support a strong small molecule -- or new chemical entity (NCE) -- portfolio. The licensing of Neogenesis' ALIS technology, announced in July 2001, is enhancing Celltech's small molecule capabilities through access to state of the art compound screening capabilities. A gene family focus for small molecule projects enables Celltech to rapidly build expertise, particularly around compound libraries, assay formats, and chemistry approaches.

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, Chimica e Tecnologia Farmaceutiche, Scienze Biologiche, Medicina e Chirurgia (e corrispondenti lauree specialistiche) e Biotecnologie (solo lauree specialistiche). PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 12

1(87(&3+$50$3/& 5(*1281,72 



:HEVLWH http://www.neutecpharma.com/



&OLQLFDO6FLHQFHV%XLOGLQJ0DQFKHVWHU8.



 

1HXTec Pharma plc is a biopharmaceutical company formed in 1997 which specialises in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. In February 2002 the Company’s equity was admitted on the Alternative Investment

Market (“AIM”) of the London Stock Exchange. The development of 1HXTec's products differs from the traditional approach used by conventional pharmaceutical companies which screen numerous chemical compounds for activity against bacteria and fungi. Many of these compounds will be too toxic for human use. In contrast, NeuTec identifies naturally occurring potentially protective antibodies from patients who have recovered from bacterial and fungal infections and then uses these to generate “grabs” to treat these infections. As a result, these “grabs” are likely to be intrinsically safer than antibiotics.



6WDJHVSHUVWXGHQWLGHO&RUVRGL/DXUHDLQMedicina e Chirurgia

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 13

9(51$/,6

:HEVLWH http://www.vernalis.com/

9HUQDOLV5HVHDUFK/LPLWHG



  Vernalis is an integrated biopharmaceutical company that discovers, develops and commercialises drugs to treat central nervous system diseases such as Parkinson's disease, sexual dysfunction, obesity and diabetes. The Company is internationally recognised for its expertise in the field of serotonin, a key neurotransmitter involved in neurological, psychiatric and eating disorders. In 2002 Vernalis saw the launch of its most advanced product, frovatriptan for the acute treatment of migraine, in the key US and European markets.



6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, Chimica e Tecnologia Farmaceutiche e corrispondenti lauree specialistiche (Analytical Chemistry Department).

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 14



*(50$1,$

$9(17,6

:HEVLWH http://www.aventis.com/main/page.asp

$YHQWLV3KDUPD'HXWVFKODQG)UDQNIXUWDP0DLQ



 

 In the research center of the pharmaceutical company Aventis, located in Frankfurt (Germany), a group of about 40 people is dedicated to search for biologically active small molecules from natural sources, like plants, bacteria and fungi. The natural products group is part of Aventis global lead generation organisation and is working as partner of research groups in all Aventis centers in Germany, France and the US. Four groups within the department are involved in peparation/fermentation of resources, of biological testing, identification of active compounds by various physico/chemical methods (HPLC-UV, HPLC-MS) and of isolation of pure compounds. They are supported by groups involved in fermentation scale up and structural elucidation of the compounds purified, mainly by NMR. The research activity of the department is optimised to guarantee a maximum output of purified structures with biological activity by streamlining the processes and using highly automated systems whenever possible. The center hosts one of the biggest collections of microbial strains in pharmaceutical industry. Access to plant samples from biological “hot spots” is managed by partnering with partner research groups worldwide.





6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, Chimica e Tecnologia Farmaceutiche, Scienze Biologiche (e corrispondenti lauree spcialistiche) e

Biotecnologie (solo lauree specialistiche) 



PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 15

&2/(<3+$50$&(87,&$/

:HEVLWH http://www.coleypharma.com/index_flat.html



&HQWURGL/DQJHQIHOG

Coley Pharmaceutical Group discovers, develops and commercializes a new class of drugs that stimulate the human immune system to treat and prevent cancer, asthma, allergy and infectious diseases. Based on proprietary CpG oligonucleotides, or CpG oligonucleotides, a family of molecules that were discovered to mimic the immunostimulatory properties of bacterial DNA, Coley's products activate innate and adaptive immune responses to fight disease. The company's lead product, CpG 7909, is currently in Phase I and Phase I/II clinical trials both as a monotherapy drug and as part of multi-drug regimens to treat various types of cancer. Additional Phase I/II clinical trials are ongoing in infectious disease, as well as vaccine efficacy trials. Coley's novel Human Cell Screening (HCS) discovery platform allows for the rapid development and validation of new product candidates. Coley focuses its internal product development efforts on cancer and on selected infectious diseases, and collaborates with partners for development of products in other infectious diseases, allergy and asthma and cancer vaccines. Coley is a private company with Executive Offices in the United States and Research and Development Operations in Langenfeld, Germany and Ottawa, Canada. The Coley Site in Germany, where the student will be working, is located in Langenfeld. Langenfeld, a pleasant town on the Rhine situated between the cities Düsseldorf and Cologne, can easily be reached by public transportation.







6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Farmacia, Chimica e Tecnologia Farmaceutiche, e

Biotecnologie (solo lauree specialistiche)

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 16

2/$1'$

25*$121$.=212%(/

:HEVLWH http://www.organon.com/authfiles/index.asp

&HQWURGL2VV



Organon, a business unit of Akzo Nobel, is a research-based, market-driven pharmaceutical company with operations throughout the world. Organon discovers, develops, manufactures and markets a wide range of high-quality, original prescription medicines, including products in the fields of gynecology, mental health, immunology, thrombosis, and anesthesia. With about 1100 co-workers, the major part of Organon’s R&D is situated in Oss, a town in the south of the Netherlands. Within this organisation, The Department of Pharmaceutics hosts a considerable amount (>20) of students every year. Research topics are in the field of pharmaceutical and analytical technology, for example on alternative dosage forms, pharmaceutical processes or formulation principles.

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, Chimica e

Tecnologia Farmaceutiche e corrispondenti lauree specialistiche.





PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 17

,17(59(7,17(51$7,21$/%9

:HEVLWH http://www.intervet.com/

,QWHUYHW,QWHUQDWLRQDOEY 5HVHDUFK&HQWHUGL%R[PHHU 

Intervet, a business unit of Akzo Nobel showed sales of EUR 1.081 million in 2002. The company is focused on the research on animal health products. (vaccines for the prevention of infectious diseases, anti-infectives, anti-parasitics, feed additives, products for fertility management, other pharmaceutical specialties. Long-term success in the global animal health market is driven by innovation and the application of “high-tech” methodology in research and production. As a result, R&D has been and continues to be one of the key investment areas for Intervet. Annual investment in research and development exceeds 10% of sales and is supported by more than 15% of Intervet’s total workforce.

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Scienze Biologiche, Medicina e Chirurgia (e corrispondenti lauree specialistiche) e Biotecnologie (solo lauree specialistiche). PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 18

'$1,0$5&$

/(23+$50$

:HEVLWH http://www.leo-pharma.com/w-site/leo/docs.nsf

&HQWURGL%DOOHUXS

LEO PHARMA is a medium size pharmaceutical company with a particular knowledge and interest in dermatological diseases, with a vitamin D analogue for the treatment of psoriasis as our prime product. In our research, dermatological diseases such as psoriasis, atopic dematitis and acne are important targets but also areas outside dermatology such as cancer and systemic inflammation are our interest. We are about 500 people in research and development and have a fully integrated pharmaceutical setup with all specialities in-house e.g. medicinal chemistry, molecular biology, biochemistry, cell biology, pharmacology, pharmacokinetics and toxicology. Our Medicinal Chemistry Research consists of about 50 people dedicated to several different research programs with the aim to discover and develop new unique drugs to be used in serious diseases.

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, Chimica e Tecnologia Farmaceutiche (e corrispondenti lauree specialistiche)

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 19

)5$1&,$

6$12),6<17+(/$%2

:HEVLWH http://www.sanofi-synthelabo.com/



%DJQHX[UHVHDUFKFHQWHU



Sanofi-Synthelabo is a major global research-based pharmaceutical group with 32,500 employees in more than 100 countries. The company is headquartered in Paris and listed in Paris (Euronext : SAN) and in New York (NYSE : SNY). With consolidated sales of EUR 7.4 billion in 2002, Sanofi-Synthelabo ranks 7th in Europe and among the world’s top 20 pharmaceutical companies. With an R&D portfolio of 52 compounds in development, Sanofi-Synthelabo is focused on a core group of four therapeutic areas: cardiovascular disease and thrombosis; diseases of the central nervous system; internal medicine; and oncology. Discovery Research of Sanofi-Synthelabo employs more than 1100 permanent researchers. It is involved in four major therapeutic areas : cardiovascular and thrombosis, central nervous system, internal medicine and immuno-oncology. In Europe, there are 10 research centers, which are located in France (Bagneux, Rueil-Malmaison, Chilly-Mazarin, Montpellier, Toulouse, Labège, Strasbourg), Italy (Milan), Spain (Alcobendas) and Hungary (Budapest).The Bagneux research center, located in the close vicinity of Paris, is specialized in Central Nervous System research. The main areas include psychiatric disorders (schizophrenia, depression, anxiety, etc…), neurodegenerative diseases (Alzheimer's and Parkinson's diseases, multiple sclerosis, stroke, head injury), sleep disorders and drug of abuse. About 150 researchers with expertise in medicinal chemistry, neurochemistry, psychopharmacology and neurophysiology work in Bagneux.

6WDJHVSHUVWXGHQWLGHL&RUVLGL/DXUHDLQ Farmacia e Chimica e Tecnologia Farmaceutiche

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 20

3,(55()$%5(

:HEVLWH http://www.pierre-fabre.com/



&HQWURGL&DVWUHV KWWSZZZFUSIQHWHQJOLVKKRPHKWP 

Since 1991, the Pierre Fabre Research Centre (CRPF) focused its research efforts on 3 main lines characterised by an urgent therapeutic need, i.e. cancer, cardiovascular diseases and disorders of the central nervous system. Students willl join a division of cardiovascular pharmacology whose research program is related to the regulation of transcription factors involved in metabolic diseases and atherosclerosis. This program is supported by both a pharmacological division (2 scientists and 6 technicians) and a medicinal chemistry division which provides novel agents for further evaluation. Both LQ YLWUR (reporter gene assay, macrophage and adipocyte differentiation, vascular cell inflammation) and in vivo (rodent models of insulin resistance, diabetic dyslipemia, arterial neointima thickening and immunohistochemistry) experiments are carried out to screen candidates.

Students will participate to the LQYLYR assays and will set up/develop methods for studying plasma lipoproteins and lipid metabolism in various tissues. In order to succeed, you need some experience in spectro-photometry, chromatography, and biochemical analyses and are interested to work with laboratory animals (species: rat, mouse, hamster - type: oral and parenteral drug administration, blood and tissue sampling).

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Farmacia, Chimica e Tecnologia Farmaceutiche, Scienze Biologiche, Medicina e Chirurgia (e corrispondenti lauree specialistiche)

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 21

*8(5%(7

:HEVLWH http://www.guerbet-group.com/index_va.html

&HQWURGL$XOQD\VRXV%RLV NPGD3DULJL 

 

 Guerbet is a pharmaceutical firm specialised in Contrast Media for Radiology. 130 employees are working in our R&D center and our R&D expenditures are 20 M EU. Our Research center is localised at Aulnay sous Bois (15 km from Paris). The skills developed by our Research group are :drug discovery, analytical pharmacokinetic -in vitro, ex vivo, in vivo biology, -experimental imaging, -industrial property, Three main targets are worked for medical diagnostic: cardiovascular diseases, oncology, inflammatory and degenerative diseases



6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, o Chimica e Tecnologia Farmaceutiche, Scienze Biologiche (e corrispondenti lauree specialistiche) o Biotecnologie (solo lauree specialistiche) PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 22

&($

&HQWUHG (WXGHV$WRPLTXHV &($ 'HSDUWPHQWRI&HOOXODU5HVSRQVHVDQG'\QDPLFV

'HSDUWPHQW '5'& /DERUDWRLUHGH3K\VLRORJLHFHOOXODLUHYpJpWDOH 3&9 *UHQREOH



The mechanisms of control of most allosteric enzymes involved in the biosynthetic pathways leading to essential aminoacids in plants and microorganisms are still unknown. The student will receive a practical training in molecular biology, biochemistry, enzymology and crystallogenesis in order to characterize the structure/function relationships between an allosteric enzyme and its effector. This work will be carried out in close interaction with the Institut of Structural Biology of Grenoble (IBS) and the Synchrotron of Grenoble (ESRF).

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Scienze Biologiche e Biotecnologie (solo lauree specialistiche)

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 23

%5(7$*1(%,27(&+12/2*,(9(*(7$/(



:HEVLWH http://www.cerafel.com/en/default.html

&HQWURGL6DLQW3ROGH/pRQ

 

 Thanks to research contracts within regional vegetable branches and externally and because of its membership to the technological innovation network in Brittany (Bretagne Innovation) BBV has become a priviliged partner not only to monitor seed selection but also to advise agro-alimentary agriculturists and industrials.

Resources include a 19-strong team comprising 8 researchers and engineers, 1300 M2 of laboratories (molecular biology, cellular biology, phytopathology), 400 M2 of glass houses and 100 M2 of climatized greenhouses and a specialised team to ensure implementation of the results.





6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, Chimica e Tecnologia Farmaceutiche, Scienze Biologiche, Medicina e Chirurgia (e corrispondenti lauree specialistiche) e Biotecnologie (solo lauree specialistiche). PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 24

+5$3+$50$

:HEVLWH http://www.hra-pharma.com/fr/index2.html

5HVHDUFKDQG'HYHORSPHQW+5$3KDUPD3DULV

 HRA Pharma was created by two professionals from the pharmaceutical realm, André Ulmann, MD, and Henri Monod. Their founding vision was to develop and commercialize health products for which there is a strong medical need and in indications that big pharmaceutical companies are reluctant to pursue. HRA Pharma identified emergency contraception as its first priority and developed its first product in this indication. Norlevo® (also marketed under the trademarks Vikela®, Vika®, and Duofem®) is the world's first emergency contraceptive available on an OTC basis. HRA Pharma has played an integral part in the introduction of emergency contraception to women worldwide. In the nearly four years since Norlevo® levonorgestrel emergency contraception was first launched in France, HRA Pharma has succeeded in registering its emergency contraceptive products in over 50 countries and obtaining non-prescription status in no less than in 25 of them. HRA Pharma’s commitment to emergency contraception extends to new research projects, including the expansion and improvement of existing methods as well as the development of new approaches. HRA Pharma has also engaged in a number of initiatives in the service of public health, including: Offering reproductive health training for health professionals and contraceptive users in France via an interactive web site; Conducting research activities in collaboration with public organizations (INSERM, Population Council, NIH) in an effort to evaluate the medical and sociological consequences of the large scale use of emergency contraception; Participating in humanitarian actions aimed to improve Norlevo® access in developing countries in collaboration with non-profit organizations (UNFPA, USAID) in the form of Norlevo® donations and participation in training programs.

The company has initiated the development of another innovative contraceptive product which should reach the market within 3 years. In addition, HRA Pharma has identified other related areas where its expertise will be useful. In the coming months, it will commercialize new products useful for patients and health professionals. Headquartered in Paris, France, HRA Pharma is staffed by a core group of highly experienced professionals complemented by a large network of committed senior consultants. Its operations are focused on strategic project management, logistics, marketing and pharmaceutical and regulatory affairs, with production and sales activities subcontracted by means of privileged partnerships.

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Farmacia, Chimica e Tecnologia Farmaceutiche, Medicina e Chirurgia





 PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 25

25)$*(1

:HEVLWH http://www.orfagen.com/

3DUF7HFKQRORJLTXHGX&DQDO 5DPRQYLOOH6W$JQH 

6WDJHVSHUVWXGHQWLGHL&RUVLGL/DXUHDLQFarmacia, Chimica e Tecnologia Farmaceutiche

PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 26



,5/$1'$

35(852&+(0



:HEVLWHhttp://www.preurochem.com/

%DOO\YRODQH%XVLQHVV3DUN &RUN 

PR euroCHEM is Centre in Research and development and Custom Synthesis for the PharmaChem Industries. We are involved in the synthesis of Pharmaceutical Actives Ingredient and Intermediates for Drugs. The Student should have a basic knowledge in Organic Synthesis, familiarity with the analytical means such HPLC, IR, NMR and GC.

6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Chimica, Chimica Industriale, Farmacia, Chimica e Tecnologia Farmaceutiche (e corrispondenti lauree specialistiche) PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 27

63$*1$

,67,78722)7$/02/2*,&2'($/,&$17(



:HEVLWH http://www.oftalio.org/

 In the R&D Department we undertake a large number of projects in the following fields of research: Refractive surgery, Inflammation, Prevention of Blindness, Cataract Surgery, Low Vision, Biomaterials-bioadhesives, Molecular Biology.

In refractive surgery we have the most advanced technology in Europe. In addition, various instruments and surgical designs for intraocular lenses have been patented by members of the Instituto Oftalmológico de Alicante (IOA). The IOA, at the forefront in Spain in the field of cataract surgery, has achieved two important advances with the use of the laser for the treatment of cataracts and the launching of a new generation of multifocal intraocular lenses.Another important project from 2001 is the MICS “Minimal Incision Cataract Surgery”. Dr. Alio has developed and successfully applied the concept of microincision in cataract surgery. This new technique can be applied in 80% of the cases of cataracts. The patients of the IOA have been the first to benefit from this development. The MICS technique will mark the future of cataract surgery for its higher degree of safety, rapidity and for the reduced level of risk, complications and long term effects for the patient. he IOA has also developed a new concept of refractive lens that can be changed inside the eye allowing the optic of the lens to be replaced leaving the haptic in place. The IOA is the only centre in the world that has this technique, created by our specialists, who at present are researching two new types of optics that will improve the prospects for the patient. This lens called Duet Kelman will replace all existing lenses in the future, as it allows manipulation of the optic of the eye using a minimal incision.



6WDJHV SHU VWXGHQWL GHL &RUVL GL /DXUHD LQ Farmacia, Chimica e Tecnologia Farmaceutiche, Medicina e Chirurgia PROGETTO LEONARDO UNIROMA-PHARMA-TRAINING - GUIDA PER I CANDIDATI (versione del 23-9-03) 28















3HUXOWHULRULLQIRUPD]LRQLVFLHQWLILFKHULYROJHUVLD

Dr. Luciano Saso Facoltà di Farmacia Dipartimento di Farmacologia delle Sostanze Naturali e Fisiologia Generale Universita' di Roma "La Sapienza" P.le Aldo Moro 5, 00185 Roma Fax. 06-49912480 E-mail: [email protected]

I n bocca al lupo!